The 15‐year US Osteosarcoma Surveillance Study was initiated in 2003 to evaluate a potential association between the recombinant human parathyroid hormone analog teriparatide (Forteo; Eli Lilly and Company, Indianapolis, IN, USA) and osteosarcoma in humans. This evidence concerns the gene PTH and osteosarcoma.